Muscarinic cholinergic receptor blockade impairs free fatty acid mobilization during fasting in pigeons (Columba livia).
The effects of intracerebroventricular pretreatment with muscarinic (scopolamine or methylscopolamine; 2.7 nmol or 5.4 nmol) or nicotinic (mecamylamine, 2.7 nmol or 5.4 nmol) cholinergic receptor antagonists on plasma free fatty acid increases induced by intracerebroventricular injections of carbachol in conscious resting pigeons (Columba livia) were examined. Plasma glucose levels were also measured throughout the experiments. Pretreatment with methylscopolamine suppressed the lipolytic effect of carbachol injections, while mecamylamine left this response unchanged. Neither carbachol treatment alone, nor the pretreatments with cholinergic agents affected glucose levels. Subsequently, the effects of intracerebroventricular injections of methylscopolamine were investigated in 24-h food-deprived pigeons. The increase in free fatty acid levels after fasting was of a magnitude similar to that observed after carbachol treatment; intracerebroventricular injections of methylscopolamine (5.4 nmol) transiently but powerfully decreased plasma free fatty acids in 24-h food-deprived pigeons to levels comparable to those of free-feeding animals. The fasting-induced decrease in glucose levels was not affected by this treatment. These data indicate that the lipolytic response induced by carbachol may be mediated by central muscarinic cholinergic receptors and that this central cholinergic mechanism partially contributes to plasma free fatty acid increases observed during fasting. Furthermore, the absence of effects on glucose levels suggests that these cholinergic mechanisms participate selectively in the lipolytic component of the metabolic response to fasting.
de Azevedo
L C
LC
Department of Physiological Sciences, CCB, Federal University of Santa Catarina, Florianópolis SC, Brazil.
Zizemer
J R
JR
Häckl
L P N
LP
Marino-Neto
J
J
Paschoalini
M A
MA
D000818:Animals; D001786:Blood Glucose; D002217:Carbachol / Q000494:pharmacology; D018679:Cholinergic Agonists / Q000494:pharmacology; D010856:Columbidae / Q000378:metabolism*; D005215:Fasting / Q000378:metabolism*; D005230:Fatty Acids, Nonesterified / Q000097:blood*; D007276:Injections, Intraventricular; D008066:Lipolysis / Q000187:drug effects / Q000502:physiology; D008297:Male; D018727:Muscarinic Antagonists / Q000494:pharmacology*; D019832:N-Methylscopolamine / Q000494:pharmacology; D010276:Parasympatholytics / Q000494:pharmacology; D011976:Receptors, Muscarinic / Q000378:metabolism*; D012601:Scopolamine / Q000494:pharmacology*
D001786:Blood Glucose; D018679:Cholinergic Agonists; D005230:Fatty Acids, Nonesterified; D018727:Muscarinic Antagonists; D010276:Parasympatholytics; D011976:Receptors, Muscarinic; D002217:Carbachol; D012601:Scopolamine; D019832:N-Methylscopolamine